芪参益气滴丸具有益气通脉、活血止痛之功，是目前冠状动脉粥样硬化性心脏病临床治疗推荐用药，但未经过系统整理、归纳，缺乏相应的指导性文件。为进一步提高临床医生对该药的认识，更好地指导其临床合理用药，特邀请全国临床与科研一线专家制订本临床应用专家共识。本共识在系统检索梳理芪参益气滴丸上市以来的临床及基础研究证据的基础上，采用国际临床医学专家共识研制方法，对芪参益气滴丸疾病治疗的优势环节、用药方案与时机、剂量、疗效特点、用药安全及注意事项等问题等进行了推荐或建议，通过了专家评审与论证，为指导芪参益气滴丸的临床合理用药提供参考。该共识已通过中华中医药学会的审核，并进行了发布，编号为GS/CACM 366—2024。

Qishenyiqi Dropping Pills, renowned for their efficacy in replenishing qi, invigorating blood circulation, and mitigating pain, are presently advocated for the clinical management of coronary atherosclerotic heart disease. Despite their therapeutic promise, there has been an absence of comprehensive synthesis or summarization of their applications, alongside a dearth of authoritative guidelines. To deepen clinicians' comprehension of this pharmaceutical and to steer its judicious clinical utilization, we have convened a panel of frontline clinical and research experts nationwide to craft this Expert Consensus on Clinical Application. This consensus is the product of meticulous scrutiny and analysis of clinical and fundamental research evidence accrued since the market introduction of Qishenyiqi Dropping Pills. Employing internationally recognized methodologies for formulating clinical medical expert consensus, it delineates recommendations on the therapeutic advantages, medication protocols and timing, dosage, efficacy profiles, safety, and precautions associated with Qishenyiqi Dropping Pills. Having been meticulously reviewed and validated by experts, this consensus serves as a beacon for the rational clinical deployment of Qishenyiqi Dropping Pills. Endorsed by the China Association of Chinese Medicine (CACM), this consensus has been formally promulgated under the document identifier GS/CACM 366-2024.

R972

国家自然科学基金面上项目（82374252）；上海市科学技术委员会“科技创新行动计划”医学创新研究专项（23Y31920200）